AVITA Medical to Announce First Quarter 2026 Financial Results
Rhea-AI Summary
AVITA Medical (NASDAQ: RCEL) will report its first quarter 2026 financial results after U.S. market close on Thursday, May 14, 2026. A conference call and webcast will be held at 1:30 p.m. PT (May 15, 2026, 6:30 a.m. AEST) to discuss results and business highlights. Replay will be available on the company's investor relations Events page.
Positive
- None.
Negative
- None.
News Market Reaction – RCEL
In the Apr 24 session, RCEL gained 3.00%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 15 | Founder's award | Positive | -7.9% | Founder received American Burn Association Lifetime Achievement Award recognition. |
| Apr 14 | Clinical data update | Positive | +14.1% | Positive interim Cohealyx-I data showing faster time to skin graft. |
| Apr 08 | Government contract win | Positive | +10.7% | 10-year BARDA agreement worth up to $25.5M for burn preparedness. |
| Apr 07 | Conference presentations | Positive | +5.9% | Extensive ABA 2026 presence with RECELL and Cohealyx-linked data. |
| Feb 23 | Investor conference | Positive | +11.1% | Participation in TD Cowen 46th Annual Health Care Conference. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-specific news has often coincided with double-digit single-day moves, mostly positive, with one notable negative divergence on an honorary award headline.
Over the last few months, AVITA Medical has issued several impactful updates. On April 8, 2026, it secured a 10-year BARDA agreement worth up to $25.5 million, followed on April 14 by positive interim Cohealyx-I data showing accelerated time to skin grafting. Multiple ABA 2026 presentations on April 7 and participation in the TD Cowen conference on February 23 underscored active clinical and investor outreach. Today’s earnings date notice fits into this cadence of frequent communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
VALENCIA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that it will report its first quarter 2026 financial results after the close of the U.S. financial markets on Thursday, May 14, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, May 15, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.
First Quarter 2026 Webcast and Conference Call Information
To listen to the conference call webcast, please register and join using the following link: https://edge.media-server.com/mmc/p/t54pdcd4.
To participate in the live earnings conference call, please register in advance to receive dial-in details and a personal PIN using the following link: https://register-conf.media-server.com/register/BI27b7d18fc52c43599f75b727d38f8883.
For those unable to participate in the live broadcast, a replay will be available on the Events page of the Company’s investor relations website at: https://ir.avitamedical.com/events-and-presentations.
About AVITA Medical, Inc.
AVITA Medical® is a leading therapeutic acute wound care company delivering transformative solutions. Our technologies are designed to optimize wound healing, effectively accelerating the time to patient recovery. At the forefront of our platform is RECELL®, approved by the FDA for the treatment of thermal burn and trauma wounds. RECELL harnesses the healing properties of a patient’s own skin to create Spray-On Skin™, offering an innovative solution for improved clinical outcomes at the point-of-care. In the U.S., AVITA Medical also holds the exclusive rights to market, sell, and distribute Cohealyx®, an AVITA Medical-branded collagen-based dermal matrix, and the exclusive rights to manufacture, market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix.
In international markets, RECELL is approved to promote skin healing in a wide range of applications, including thermal burn and trauma wounds. RECELL and RECELL GO® are CE-marked in Europe; RECELL is TGA-registered in Australia and PMDA-approved in Japan.
To learn more, visit www.avitamedical.com.
Investor & Media Contact:
Ben Atkins
Phone +1-805 341 1571
investor@avitamedical.com | media@avitamedical.com
Authorized for release by the Chief Financial Officer of AVITA Medical, Inc.
©2026 AVITA Medical. AVITA Medical®, Cohealyx®, RECELL®, RECELL GO®, and Spray-On Skin™ are trademarks of AVITA Medical. PermeaDerm® is a registered trademark owned by Stedical Scientific, Inc. All other trademarks are the properties of their respective owners.
